Indeed, KRAS and NRAS mutant tumours and to a lesser extent BRAF mutant tumours are highly sensitive to combinations of PARP with MEK/ERK inhibitors in vitro, whereas for KRAS mutant models this evidence is available in vivo. This evidence concerns the gene PARP1 and neoplasm.